Diploma PLC DPLM.L
Composite 60/100; the shares have moved about 36% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 25/100 — a strong mark against it.
Growth ranks 78/100 — a strong point in its favour. Balance-sheet strength ranks 72/100 — a moderate point in its favour. Quality ranks 71/100 — a moderate point in its favour.
Valuation ranks 25/100 — a strong mark against it. Income ranks 26/100 — a moderate mark against it.
What the company does Diploma PLC supplies specialized technical products and services across Controls, Seals, and Life Sciences. Its offerings include cabling, sealing solutions, medical devices, and diagnostic equipment, serving sectors like healthcare, aerospace, and industrial automation.
Key financials Diploma reports strong profitability with ROE 18.9%, ROA 10.8%, and ROCE 34.1%. Margins are healthy: gross 47.5%, operating 19.7%, net 11.5%. Revenue grew 16.8% while EPS grew 4.5%, supported by a solid balance sheet (debt/equity 0.47).
Stock health The stock shows positive momentum: 12-month return 33.29%, 6-month 31.55%, and RSI(14) at 47.70. Quality pillars are strong (Quality 73.8), but valuation ranks low (Valuation 21.3) despite high margins and growth.
Price vs fair value Diploma trades at a **PREMIUM of 50.90%** to our fair-value estimate and a **discount of 12.76%** to the 12-month analyst target. - Fair-value premium of 50.90% reflects high forward P/E 28.82 and EV/EBITDA 27.33 (Valuation 21.3). - Discount to target suggests potential upside despite rich multiples (analyst count 16). - Strong ROCE 34.1% and Piotroski F-Score 7/9 support quality but not current valuation. - Momentum pillar at 69.4% aligns with 33.29% 12-month return.
Looking forward Forward P/E improves to 28.82 from 54.04, signaling earnings growth expectations. PEG of 0.33 suggests undervaluation relative to growth, but high multiples and premium to fair value temper near-term upside. Monitor margin sustainability and execution in Life Sciences.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.